Table 1.

Enrolled patient demographics and disease characteristics

Characteristics	Category	N/value	Percent
Gender	Female	11	36.7
	Male	19	63.3
Race	White	26	86.7
	Black/African American	4	13.3
Ethnicity	Non-Hispanic	29	96.7
	Unknown	1	3.3
Age	Median	47.5
	Minimum	28
	Maximun	74
	Mean	49.2
	SD	11.9
ECOG PS	0	21	70
	1	9	30
Stage at presentation	I	1	3.3
	II A	2	6.7
	II B	0	0
	III A	0	0
	III B	2	6.7
	III C	3	10
	IV	22	73.3
Sites of metastasis	Liver	22	73.3
	Lung	7	23.3
	Lymph node	5	16.7
	Bone	2	6.7
	Ileum	3	10
	Peritoneum	3	10
	Other	5	16.7
Molecular findings	KRAS	KRAS
	MU/WT/Unknown	10/12/8
	NRAS	NRAS
	MU/WT/Unknown	4/17/9
	BRAF	BRAF
	MU/WT/Unknown	0/21/9
	MMR	MMR
	Stable/Unstable/Unknown	16/2/12
	MSI	MSI
	MSI-H/MSI-L/Unknown	2/9/19

Demographics for the patients in this trial are listed. ECOG performance score (PS), tumor stage at presentation, and observed sites of metastasis upon trial enrollment are displayed. A subset of patient tumors were tested for mutant (MU) or wildtype (WT) status of KRAS, NRAS, and BRAF. DNA mismatch repair (dMMR) stability and microsatellite instability (MSI) status (high versus low) were also assessed